News | April 10, 2026
Lupin Foundation expands NCD care access in Rajasthan with new diagnostic corners
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
Landmark procedure restores 32-year-old CKD patient’s health, highlighting how public insurance is widening access to advanced renal care
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
Subscribe To Our Newsletter & Stay Updated
